An important finding of our study is an upregulation of a wide range of receptor tyrosine kinases in tumours such as the vascular endothelial growth factor receptor 2 (VEGF2/KDR), EGFR and ERBB2, ephrin type‐A&B receptor (EPHA & EPHB2), platelet‐derived growth factor receptor, the RET and the MER, MET and RON proto‐oncogenes. This evidence concerns the gene ERBB2 and neoplasm.